Regulatory Submissions, Information, and Document Management Forum

As the medical and scientific writing community manage unprecedented levels of new drug development, what role will generative AI (GenAI) play moving forward? Increasingly, BioPharma companies have turned to AI to augment their workforces, make teams more efficient, and accelerate submission timelines.

This session will look at how Yseop has partnered with some of the top pharmaceutical companies in the world to address their unique content automation requirements. Speakers will review three common use cases for GenAI and the dramatic results pharma companies have seen across preclinical and clinical document production.

Featured Topics

• How is GenAI impacting medical writers and the new drug development process?
• What are the unique requirements in life sciences for AI implementations compared to other, less regulated industries?
• What results can pharma companies anticipate? Dramatic improvements in quality and speed including hundreds of thousands of hours saved in writing time and more than 50% reduction in review time.